Benazepril Articles
Teva's 1st-qtr profit more than triples
6 May 2009
Novartis looks to single-pill BP drugs after study
15 December 2008
Teva's 2nd-qtr 2007 net sales rise 10% to $2.39B
20 August 2007
Teva resumes shipment of generic Lotrel in USA
18 June 2007
Teva gets final FDA OK for generic Lotrel
28 May 2007
Combined bp drug Azor discussed at ASH
28 May 2007
Novartis' 1st-qtr 2007 profit up 11% to $2.17B on strong sales of cancer drugs and Diovan
30 April 2007
Novartis sees 16% sales jump in first three qtrs of 2006 beating consensus estimates
30 October 2006
Teva gets tentative FDA OK for generic Lotrel
17 July 2006
Novartis sees strong performance with record results in 2005
30 January 2006
Novartis nine-month net income leaps 21%
25 October 2004
Teva on track to sell generic Lotensin in the USA
17 November 2003
Novartis' sales on track in third quarter; profits rise 7% as Diovan, Gleevec deliver
27 October 2003
American football hero Montana backs Novartis' Lotrel
8 September 2003
Profits flat at Novartis despite sales growth
21 April 2003
Analysts see threat to Novartis' Lotrel
6 January 2003
Novartis sales grow 12% in 2nd qtr
29 July 2002
Double-digit turnover growth for Novartis in 2001
11 February 2002
Double-digit turnover growth for Novartis
11 October 2001
Novartis' six-month 2001 net income jumps 10%, sales up 11%
16 August 2001
Vita completes final analysis of Ph III trials
18 June 2001
Novartis expects five new products to drive growth in 2001
15 February 2001
Novartis puts in solid 1st-half performance
21 August 2000
"Underlying Quality" In Novartis' Growth
2 November 1998
Novartis Restructures After Disappointing First Half
1 September 1998
Modest Rise In Sales At Novartis Lower Than Expected
22 April 1998
Health Care Fuels Strong 1997 Start For Novartis
21 April 1997
Strong Growth From Ciba In 1996 First Half
22 July 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Ciba Health Care Sales Rise 8%
29 January 1996
Ciba Gets Positive Nine-Month Reception
23 October 1995
Sales Decline 6% At Ciba In 1995 First Half
4 September 1995
Ciba Launches Lotrel In The USA
14 August 1995
Ciba Reveals Pipeline With Broad Reach
17 April 1995
ANTIHYPERTENSIVES FAIL TROUGH-PEAK CRITERIA
20 June 1994
CIBA'S BENAZEPRIL/AMLODIPINE COMBO
20 June 1994
CIBA RESULTS FOR 1993 "AS PROMISED"
4 April 1994
US DRUGSTORE AUDIT DATA FOR JULY
6 September 1993
CIBA-GEIGY Japan SETS CIBACEN GOAL
26 April 1993
NEW PRODUCTS ON JAPAN TARIFF LIST
12 April 1993
CIBA LAUNCHES CIBADREX
1 March 1993
Lotensin combination gains approval
8 June 1992
NITRATES: OLD DRUGS, BUT ONES WITH A FUTURE
20 April 1992
SANOFI, CIBA-GEIGY ON PARIBAS BUY LIST
13 January 1992
US FDA BEATS 1990 DRUG APPROVALS IN 1991
13 January 1992
Showing 1-66 of 66 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
